Century Therapeutics: Portfolio Prioritization to Extend Cash Runway Into 2026

  Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma -

- Employee headcount reduced by approximately 25 percent, extending cash runway into 2026 -

- Phase 1 study of CNTY-101, Company's lead candidate targeting CD19, in relapsed/refractory B-cell lymphoma remains on track; No impact to partnered programs with Bristol Myers Squibb -

https://finance.yahoo.com/news/century-therapeutics-announces-internal-portfolio-210100296.html